Applications of 2-Chloro-Alpha-[2-Dimethylaminoethyl]Benzhydrol Hydrochloride in Industrial Manufacturing

As a manufacturer with deep expertise in fine chemical synthesis and downstream collaboration, we supply 2-Chloro-Alpha-[2-Dimethylaminoethyl]Benzhydrol Hydrochloride for well-established industrial sectors where consistent quality, regulatory compliance, and batch reproducibility are required. The following application scenarios outline real-world integration in industries with clearly defined quality benchmarks and usage conventions.

1. Pharmaceutical Intermediate for Antihistamine Synthesis

This compound serves as a critical intermediate in the multi-step synthesis routes for second-generation antihistamine APIs. Its molecular structure facilitates the assembly of active pharmaceutical ingredients designed for allergy medications, where stringent impurity controls and traceability are crucial throughout synthesis and purification stages.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US Pharmacopeia (USP) and European Pharmacopoeia (EP) monograph guidance for intermediates
• FDA CFR Title 21 (Part 211, 314 for APIs)
• REACH regulations on chemical safety and traceability

Typical usage ratio

• 0.85–1.05 molar equivalents per target API batch, proportion adjusted based on reaction efficiency and final yield optimization

Downstream process integration

• Dosed during multi-step condensation or reduction stages; often coupled with base or acid catalysis in controlled reactors
• Followed by extraction, recrystallization, and purification prior to downstream processing

Final product types

• Tablet and capsule antihistamine drugs (e.g., selected second-generation allergy therapeutics)
• Prescription and OTC oral suspension formulations

2. API Building Block for Central Nervous System (CNS) Active Drugs

Major CNS pharmaceutical producers procure this raw material as a foundational building block for active molecules targeting depression, anxiety, and related CNS disorders. The compound’s defined chirality and stability make it favorable for scalable synthesis, ensuring repeatably high conversion rates and ease of purification under industrial production constraints.

Industry compliance standards

• EU GMP Directive 2003/94/EC and Annex 15 Validation
• WHO Technical Report Series 957, Annex 2 for pharmaceutical substances
• DMF (Drug Master File) registration norms (US FDA and CFDA/China NMPA)
• Trace-level impurity control as per CP, JP pharmacopoeias

Typical usage ratio

• 0.9–1.2 equivalents, ratio determined by stoichiometric calculations and real-time analytics in analytical QC labs

Downstream process integration

• Incorporated in alkylation or amination reaction steps as a core precursor; high-purity grade material is required from start to finish

Final product types

• CNS small-molecule drugs (e.g., anxiolytics, antidepressants in oral and injectable forms)
• API intermediates for further structural modification

3. Custom Synthesis Feedstock for Contract Research and Manufacturing Organizations (CRO/CMO)

Leading CRO/CMO facilities incorporate this hydrochloride for custom molecule assembly in clinical trial material and pilot-scale runs. Manufacturing partners rely on batch-to-batch reproducibility and full-chain compliance for regulatory submissions, choosing this raw material to streamline route scouting and upscaling from laboratory development to small-scale production.

Industry compliance standards

• ISO 9001:2015 certified QMS (Quality Management System) for chemical manufacturing
• GMP audit compliance for pilot production plants (client audit-ready protocols)
• Material traceability documentation as per ICH Q11 and FDA guidelines
• Controlled Substance Precursor regulations (where applicable in destination country)

Typical usage ratio

• Adjusted between 0.95–1.10 equivalents in development runs; closely monitored as scale increases to optimize yield and purity

Downstream process integration

• Used for route development, process validation, and early-phase GMP kilo labs prior to commercial scale-up
• Typically enters via target synthesis step specific to client molecule design

Final product types

• Preclinical and clinical trial batch APIs
• Reference standards and advanced chemical intermediates

4. Fine Chemical Intermediate for Specialty Amine Derivative Production

Chemical processors utilize this material as a strategic intermediate during the synthesis of specialized tertiary and quaternary amine compounds found in advanced materials, performance coatings, and select non-pharmaceutical processing aids. Its molecular reactivity profile supports consistently high selectivity in downstream functionalization steps, especially for developing application-specific molecules.

Industry compliance standards

• REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) for compliance in the EU
• ISO 14001:2015 Environmental Management Systems during production
• Company-specific process safety controls under Process Safety Management (OSHA 29 CFR 1910.119 for US sites)
• Global Harmonized System (GHS) classification for handling and labelling

Typical usage ratio

• Between 0.70–1.00 molar equivalents, tuned for the stoichiometry requirements of the downstream modification reaction

Downstream process integration

• Reacted with alkyl halides, acid chlorides, or other electrophiles within continuous or batch reactors
• Followed by isolation and drying steps prior to final purification

Final product types

• Specialty tertiary amine intermediates (for electronics, catalysis, or advanced surfactants)
• Application-specific quaternary ammonium salts